Quick Answer
GILEAD SCIENCES, INC. reported Research And Development Expense of $9.11 billion for the year ending 2019.
- GILEAD SCIENCES, INC. showed an increase of +81.5% in Research And Development Expense from 2018 to 2019.
- This data is from GILEAD SCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2020.
- XBRL data for this metric is available from 2011 to 2019 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $458.21 million | Q2 2012: $396.24 million | Q3 2012: $465.83 million | Q1 2013: $497.63 million | Q2 2013: $523.90 million | Q3 2013: $546.24 million | Q1 2014: $595.00 million | Q2 2014: $584.00 million | Q3 2014: $630.00 million | Q1 2015: $696.00 million | Q2 2015: $818.00 million | Q3 2015: $743.00 million | Q1 2016: $1.27 billion | Q2 2016: $1.48 billion | Q3 2016: $1.14 billion | Q1 2017: $931.00 million | Q2 2017: $864.00 million | Q3 2017: $789.00 million | Q1 2018: $937.00 million | Q2 2018: $1.19 billion | Q3 2018: $939.00 million | Q1 2019: $1.06 billion | Q2 2019: $1.16 billion | Q3 2019: $4.99 billion | Q1 2020: $1.10 billion.
- Over the full 9 years of available data (2011 to 2019), GILEAD SCIENCES, INC.'s Research And Development Expense has grown by 640.8%.
- Historical annual values: Fiscal year 2019: $9.11 billion | Fiscal year 2018: $5.02 billion | Fiscal year 2017: $3.73 billion | Fiscal year 2016: $5.10 billion | Fiscal year 2015: $3.01 billion | Fiscal year 2014: $2.85 billion | Fiscal year 2013: $2.12 billion | Fiscal year 2012: $1.76 billion | Fiscal year 2011: $1.23 billion.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: